APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy…
~ Emphasizes Strong Cash Position, No Debt, and A Dedicated Management Team Focused on Delivering Growth and Value to Shareholders…
COLD SPRING HARBOR, N.Y., June 17, 2024 /PRNewswire/ -- Things aren't always as they seem. Take pancreatic cancer, for example. In…
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%…
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses…
The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people…
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional…
TORONTO, ON / ACCESSWIRE / April 14, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…
HOUSTON, TX / ACCESSWIRE / June 14, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…